| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Clinical Oncology and Department of Surgery, University of Wisconsin Medical Center, Madison, Wisconsin 53706
Studies have shown the importance of the delayed hypersensitivity reaction in the body's defense against cancer. Production of migration-inhibitory factors is characteristic of the delayed hypersensitivity reaction. Delayed hypersensitivity to chemically induced tumors has been demonstrated in animals by inhibition of macrophage migration.
In our study, preparations from 19 of 21 human tumors inhibited leukocyte migration. Some preparations were cytotoxic to both autogenous and allogeneic migrating leukocytes. Growth of heterologous hepatoma cells in tissue culture was not inhibited by some preparations that inhibited leukocyte migration. It appears that both cytotoxic and migration-inhibiting substances can be liberated by tumor-leukocyte interaction. Such factors may prevent interaction between cancer cells and human tumors and thereby inhibit the cellular immune response in cancer patients.
1 This work was supported by USPHS Grant CA 05953.
Received 11/24/70. Accepted 2/ 5/71.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |